-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Engineering Alternative Immune Cells as Blood Cancer Immunotherapy.

Program: Scientific Program
Session: Joint Session: Genome Engineering for Enhanced Blood Cancer Immunotherapy
Sunday, December 10, 2023, 9:30 AM-11:05 AM

Dan S Kaufman, MD, PhD

University of California San Diego, La Jolla, CA

Disclosures: Kaufman: VisiCELL Medical: Membership on an entity's Board of Directors or advisory committees; Qihan Biotech: Membership on an entity's Board of Directors or advisory committees; Shoreline Biosciences: Consultancy, Current equity holder in private company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Research Funding.

See more of: Joint Session: Genome Engineering for Enhanced Blood Cancer Immunotherapy
See more of: Scientific Program
<< Previous Presentation | Next Presentation >>